Small interfering RNA (siRNA) molecules hold immense potential for treating diseases by silencing specific genes. Encapsulated in lipid nanoparticles (LNPs), siRNA can be delivered efficiently to ...
Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid arthritis as one of the key therapeutic indications The provisional patent application describes novel nanoparticle ...
Wave Life Sciences announced WVE-007, an siRNA treatment for obesity aimed at silencing INHBE to promote sustainable weight loss. Wave Life Sciences has announced the submission of a clinical trial ...
WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or ...
The firms submitted an application to the EMA seeking to begin a Phase IIb trial of vortosiran for stroke prevention in atrial fibrillation.
The MarketWatch News Department was not involved in the creation of this content. TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech ...
siRNA therapies show promise for treating diseases like cancer and genetic disorders, but their effectiveness depends on proper delivery. A recent study found that the method of mixing siRNA with ...
Diagram of the image of being able to distinguish differences in the state of nucleic acids inside LNPs by evaluating their physical properties using NMR. Small interfering RNA (siRNA) molecules hold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results